Related Experiment Video
Updated: Dec 3, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?
Mir S Adil1, S Priya Narayanan1, Payaningal R Somanath1
1Clinical and Experimental Therapeutics, University of Georgia and Charlie Norwood VA Medical Center, Augusta, GA, USA.
Insights
Amiloride may be an ideal COVID-19 treatment due to its effects on angiotensin-converting enzyme (ACE) and cytosolic pH. This drug offers a promising alternative or add-on therapy for patients, potentially improving outcomes.
Area of Science:
- Pharmacology
- Virology
- Cardiovascular Medicine
Background:
- The COVID-19 pandemic necessitates evidence-based therapeutic strategies.
- Patients with hypertension and diabetes using ACE inhibitors face uncertainty regarding SARS-CoV-2.
- ACE inhibitors may increase ACE2, facilitating SARS-CoV-2 entry.
Purpose of the Study:
- To evaluate amiloride as a potential therapeutic agent for COVID-19.
- To explore amiloride's effects on ACE levels and cytosolic pH in the context of COVID-19.
Main Methods:
- Review of existing literature on amiloride's pharmacological properties.
- Analysis of amiloride's potential interactions with SARS-CoV-2 mechanisms.
- Assessment of amiloride's known effects on ACE and pH.
Main Results:
- Amiloride demonstrates potential to reduce ACE levels.
- Amiloride increases cytosolic pH, a beneficial effect.
- Its potassium-sparing and anti-epileptic properties are noted.
Conclusions:
- Amiloride presents a promising candidate for COVID-19 treatment.
- It may serve as an alternative or combinatorial therapy.
- Further research is warranted to validate its efficacy and safety in COVID-19 patients.
Abstract:
In the ongoing coronavirus diseases-2019 (COVID-19) crisis that caused immense suffering and deaths, the choice of therapy for the prevention and life-saving conditions must be based on sound scientific evidence. Uncertainty and apprehension are exacerbated in people using angiotensin-converting enzyme (ACE) inhibitors to control their comorbidities such as hypertension and diabetes. These drugs are reported to result in unfavorable outcome as they tend to increase the levels of ACE2 which mediates the entry of SARS-CoV-2. Amiloride, a prototypic inhibitor of epithelial sodium channels (ENaC) can be an ideal candidate for COVID-19 patients, given its ACE reducing and cytosolic pH increasing effects. Moreover, its potassium-sparing and anti-epileptic activities make it a promising alternative or a combinatorial agent.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents
Cardiomyopathy V: Interprofessional Care

